ArticleAnnals of nuclear medicine2026
The prognostic value of multiparameters derived from D-SPECT in patients with ANOCA.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThis study aimed to investigate the prognostic value of multi-dimensional parameters derived from D-SPECT in patients with ANOCA, and to identify feasible imaging markers for individualized risk stratification and therapeutic decision-making.
methodsA total of 177 ANOCA patients were included. Myocardial blood flow (MBF) was quantified globally and in three vascular territories (LAD, LCX, RCA) under rest and regadenoson-induced stress conditions. Myocardial flow reserve (MFR) was calculated globally and regionally. Other parameters included MPI findings, systolic and diastolic function, phase analysis, total perfusion defect (TPD), and transient ischemic dilation (TID). The occurrence of major adverse cardiac events (MACE) was recorded. Cox regression was used to indentify predictors of MACE. Receiver operating characteristic (ROC) curve analysis was used to determine optimal cut-off values. Survival curves were generated using the Kaplan-Meier method. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated to assess the incremental prognostic value of global MFR and MFR-LAD. Subgroup analyses stratifying patients with entirely normal coronary arteries from those with non-obstructive epicardial atherosclerosis were performed.
resultsDuring a median follow-up of 22 months (IQR 18–24 months), 23 MACE occurred in the overall cohort (23/177, 13.0%). The MACE group had a significantly higher prevalence of abnormal MPI compared to the non-MACE group (26.1% [6/23] vs. 5.8% [9/154], P = 0.001). Global MFR and territorial (LAD, LCX, RCA) MFR were significantly decreased in the MACE group. In multivariate Cox regression models, abnormal MPI (model 1 (Per-patient): HR = 4.223; 95% CI 1.658–10.756; P = 0.003; model 2 (Per-vessel): HR = 4.445; 95% CI 1.720–11.490; P = 0.002), global MFR (HR = 0.534; 95% CI 0.336–0.847; P = 0.008), and MFR-LAD (HR = 0.338; 95% CI 0.136–0.839; P = 0.019) were independent predictors of MACE. The optimal cut-off values were < 2.78 for global MFR and < 2.52 for MFR-LAD. Compared with MPI alone, the addition of global MFR and MFR-LAD provided incremental prognostic benefit (NRI 0.682–0.769; IDI 0.052–0.063). Subgroup analyses revealed no significant interaction between atherosclerosis and abnormal MPI or MFR.
conclusionD-SPECT-derived multiparameters provide incremental prognostic information in ANOCA patients beyond conventional MPI. Patients with abnormal MPI, decreased global MFR, or decreased MFR-LAD are at higher risk of MACE. Combining global and regional MFR effectively facilitates risk stratification for early prevention and intervention.
Indexed as
Identifiers
41712176What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.